{"article_title": "Bayer Moves for Norwegian Oncology Firm Algeta", "article_keywords": ["firm", "oncology", "algeta", "share", "xofigoalgeta", "norwegian", "bayer", "treatment", "talks", "moves", "representing", "seeks", "stage"], "article_url": "http://www.wsj.com/articles/SB10001424052702304281004579221530922065594", "article_text": "FRANKFURT\u2014German drug maker Bayer AG is in talks to buy Norwegian oncology company Algeta ASA for $2.42 billion, Algeta said Tuesday, as it seeks full control over potential blockbuster cancer treatment Xofigo.\n\nAlgeta said Bayer made a bid of 336 Norwegian kroner ($55.11) a share, representing a premium of 27% to the company's closing share price Monday.\n\n\"Discussions are at an early stage and further announcements may be...", "article_metadata": {"article.template": "snippet", "article.created": "2013-11-26T11:45:00.000Z", "article.section": "Business", "page.region": "na,us", "page.content.type": "Article", "twitter": {"domain": "wsj.com", "description": "German drug maker Bayer is in talks to buy Norwegian oncology company Algeta for $2.42 billion, Algeta said Tuesday, as it seeks full control over potential blockbuster cancer treatment Xofigo.", "title": "Bayer Moves for Norwegian Oncology Firm Algeta", "image": {"src": "https://si.wsj.net/public/resources/images/BN-AO097_bayer1_G_20131126065726.jpg", "alt": "Bayer is in talks to buy Norwegian oncology company Algeta for $2.42 billion", "identifier": "https://si.wsj.net/public/resources/images/BN-AO097_bayer1_D_20131126065726.jpg"}, "site": "@WSJ", "card": "summary_large_image"}, "al": {"ios": {"url": "wsj://launch?articleid=SB10001424052702304281004579221530922065594&headline=Bayer%20is%20in%20talks%20to%20buy%20Norwegian%20oncology%20company%20Algeta%20for%20%242.42%20billion&weburl=http://www.wsj.com/articles/SB10001424052702304281004579221530922065594"}}, "page.site.product": "WSJ", "keywords": "bayer algeta,bayer algeta deal,bayer xofigo,mayer acquisition,prostate cancer drug,xofigo,Algeta,ALGETA.OS,Bayer,BAYN.XE,ownership changes,acquisitions,mergers,takeovers,corporate actions,corporate,industrial news,cancer,political,general news,health,medical conditions,prostate cancer,pharmaceuticals,cancer drugs,health care,life sciences,drugs,medication", "news_keywords": "bayer algeta,bayer algeta deal,bayer xofigo,mayer acquisition,prostate cancer drug,xofigo,Algeta,ALGETA.OS,Bayer,BAYN.XE", "article.headline": "Bayer is in talks to buy Norwegian oncology company Algeta for $2.42 billion", "cXenseParse": {"candybar": {"image": "https://si.wsj.net/public/resources/images/BN-AO097_bayer1_E_20131126065726.jpg"}, "poptart": {"image": "https://si.wsj.net/public/resources/images/BN-AO097_bayer1_D_20131126065726.jpg"}}, "description": "German drug maker Bayer is in talks to buy Norwegian oncology company Algeta for $2.42 billion, Algeta said Tuesday, as it seeks full control over potential blockbuster cancer treatment Xofigo.", "apple-itunes-app": "app-id=364387007,app-argument=wsj://launch?articleid=SB10001424052702304281004579221530922065594&headline=Bayer%20is%20in%20talks%20to%20buy%20Norwegian%20oncology%20company%20Algeta%20for%20%242.42%20billion&weburl=http://www.wsj.com/articles/SB10001424052702304281004579221530922065594", "user.type": "nonsubscriber", "article.page": "Business", "page.content.format": "responsive", "article.summary": "German drug maker Bayer is in talks to buy Norwegian oncology company Algeta for $2.42 billion, Algeta said Tuesday, as it seeks full control over potential blockbuster cancer treatment Xofigo.", "page.site": "wsj", "testkeys": "B", "article.published": "2013-11-26T11:47:00.000Z", "dj.asn": "i-9e1f", "robots": "noarchive,noodp", "fb": {"app_id": 368513495882}, "article": {"internal_link_count": 2, "image_count": 1, "word_count": 340, "publisher": "https://www.facebook.com/wsj"}, "viewport": "width=device-width, initial-scale=1.0, minimum-scale=1.0, maximum-scale=1.0, user-scalable=no", "page.section": "Article", "language": "en-US", "og": {"site_name": "WSJ", "description": "German drug maker Bayer is in talks to buy Norwegian oncology company Algeta for $2.42 billion, Algeta said Tuesday, as it seeks full control over potential blockbuster cancer treatment Xofigo.", "title": "Bayer Moves for Norwegian Oncology Firm Algeta", "url": "http://www.wsj.com/articles/SB10001424052702304281004579221530922065594", "image": {"width": 553, "identifier": "https://si.wsj.net/public/resources/images/BN-AO097_bayer1_G_20131126065726.jpg", "height": 369}, "locale": "en_US", "type": "article"}, "author": "Caitlan Reeg", "article.access": "paid", "page.content.source": "WSJ Online Article", "article.origheadline": "Bayer Moves for Norwegian Oncology Firm Algeta", "article.type": "European Business News", "article.id": "SB10001424052702304281004579221530922065594", "user.exp": "default", "article.updated": "2013-11-26T11:47:00.000Z"}, "_id": "\"57477af46914bd0286fd7de2\"", "article_summary": "Algeta said Bayer made a bid of 336 Norwegian kroner ($55.11) a share, representing a premium of 27% to the company's closing share price Monday.\nFRANKFURT\u2014German drug maker Bayer AG is in talks to buy Norwegian oncology company Algeta ASA for $2.42 billion, Algeta said Tuesday, as it seeks full control over potential blockbuster cancer treatment Xofigo.\n\"Discussions are at an early stage and further announcements may be..."}